Spotlight on: clinical development of mycophenolate mofetil in multiple sclerosis.
This month's Spotlight on... focuses on the clinical development of the immunomodulatory agent mycophenolate mofetil as an adjunctive therapy for multiple sclerosis. Mycophenolate mofetil (MMF) is postulated to target several mechanisms underlying the progression of this autoimmune disease, and clinical studies to date have provided evidence for treatment-associated clinical improvements or a halt in disease progression. Ongoing phase II/III clinical trials are investigating the efficacy and safety of MMF as both a monotherapy or in combination with interferon beta-1a.
Davies
Shelley L
SL
Prous Science, Barcelona, Spain. journals@prous.com
Moral
Maria Angels
MA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000201:enzymology; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D016899:Interferon-beta; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid; D000068556:Interferon beta-1a